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ABSTRACT Cardiovascular gene therapy is a novel ap-
proach to the treatment of diseases such as congestive heart
failure (CHF). Gene transfer to the heart would allow for the
replacement of defective or missing cellular proteins that may
improve cardiac performance. Our laboratory has been fo-
cusing on the feasibility of restoring b-adrenergic signaling
deficiencies that are a characteristic of chronic CHF. We have
now studied isolated ventricular myocytes from rabbits that
have been chronically paced to produce hemodynamic failure.
We document molecular b-adrenergic signaling defects in-
cluding down-regulation of myocardial b-adrenergic recep-
tors (b-ARs), functional b-AR uncoupling, and an up-
regulation of the b-AR kinase (bARK1). Adenoviral-mediated
gene transfer of the human b2-AR or an inhibitor of bARK1
to these failing myocytes led to the restoration of b-AR
signaling. These results demonstrate that defects present in
this critical myocardial signaling pathway can be corrected in
vitro using genetic modification and raise the possibility of
novel inotropic therapies for CHF including the inhibition of
bARK1 activity in the heart.
Signaling through myocardial b-adrenergic receptors (b-ARs)
plays a critical role in normal and compromised heart function.
Congestive heart failure (CHF), a condition resulting from a
variety of cardiovascular disorders, is a leading cause of
morbidity and mortality in this country, and hospitalizations
secondary to CHF are dramatically increasing (1). When the
heart fails, a constellation of biochemical defects has been
noted which include significant alterations in the b-AR system.
Dysfunctional b-AR signaling in CHF includes receptor down-
regulation and impaired signaling through remaining receptors
(2, 3), possibly due to enhanced activity of the b-AR kinase
(bARK1) which has been shown to be elevated in human CHF
(4). bARK1 is a member of the G protein-coupled receptor
kinase (GRK) family that can phosphorylate and desensitize
agonist-occupied b-ARs (5). Despite an increased understand-
ing of the molecular defects in CHF and improvements in
pharmacological therapies for this clinical problem, successful
long-term solutions have been elusive. b-Agonists, for exam-
ple, are quite effective in acute settings, but have relatively
poor efficacy chronically due, in part, to further down-
regulation and desensitization of b-ARs (6, 7).
We have previously reported that myocardial-targeted over-
expression of b2-ARs (8) or an inhibitor of bARK1 activity (9)
in transgenic mice leads to significantly enhanced myocardial
b-AR signaling and in vivo left ventricular (LV) contractility.
In these transgenic mice, chronically enhanced b-AR-
mediated contractility achieved by two different mechanisms
(i.e., receptor up-regulation and loss of desensitization) did not
lead to any significant long-term damage to the heart, sug-
gesting that these methods of enhancing b-AR signaling are
functionally different than administration of b-agonists (10).
In addition to these transgenic animals, we have reported that
adenoviral-mediated gene transfer and overexpression of ei-
ther b2-ARs or the bARK1 inhibitor in cultured ventricular
myocytes isolated from normal adult rabbits leads to a similar
potentiation of b-adrenergic signaling (11). The bARK inhib-
itor utilized in these studies was the carboxyl-terminal 194
amino acids of bARK1 (bARKct) which competes with en-
dogenous bARK1 for binding to the bg-subunits of G proteins
(Gbg), an event required for bARK translocation to the plasma
membrane (5, 9).
The present study was performed to determine whether
ventricular myocytes isolated from a rabbit model of CHF
display molecular b-AR signaling defects similar to those seen
in human CHF and to determine potential functional effects
of adenoviral-mediated gene transfer of either b2-ARs or the
bARKct. Specifically, we attempted to rescue cellular signaling
deficiencies characterized in failing cardiomyocytes. Because
the b-AR system is such a powerful modulator of cardiac
function, the ability to manipulate b-AR density andyor
functional coupling through genetic modification is of great
interest for possible novel therapeutic modalities for CHF.
EXPERIMENTAL PROCEDURES
Tachycardia-Induced CHF in Rabbits. All procedures and
protocols were approved by the Animal Care and Use Com-
mittee of Duke University. Adult male New Zealand White
rabbits (2–4 kg) were obtained and housed under standard
conditions and allowed to feed ad lib. The rabbits were
anesthetized with a mixture of ketamine (50 mgykg) and
xylazine (2 mgykg), intubated, and mechanically ventilated. A
left thoracotomy was performed and two insulated pacing
wires were attached to the LV. Following the procedure,
animals were extubated, and after they were fully awake,
returned to their cages. Control animals underwent thoracot-
omy with implantation of pacing wires but never underwent
initiation of pacing. Custom pacemakers were designed that
weighed 9 g and were 2 cm 3 1 cm in size. The pacer was
operated by a 9 V battery that was replaced every 5 days. One
week after surgery, ventricular pacing at a rate of 360 beatsy
min was initiated. Pacing was confirmed with electrocardio-
gram at the beginning of the study and on a weekly basis for
the duration of the 3-week pacing period.
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In Vivo Hemodynamic Data. Immediately before the initi-
ation of rapid ventricular pacing, rabbits were premedicated
with ketamine (50 mgykg) and acepromazine (1–2 mgykg). A
small incision was made in the neck to expose the right carotid
artery. A 2.5-Fr micropressure transducer (Millar Instruments,
Houston) was zeroed to atmospheric pressure and passed into
the right carotid artery, down into the LV to record pressures
as well as heart rate. Confirmation of the position of the
catheter was obtained through the use of fluoroscopy as well
as the pressure waveform. Data acquisition was recorded on a
PC-based system. After 3 weeks of rapid ventricular pacing, the
pacer was disconnected from the animal and the same proce-
dure was repeated to acquire postpacing hemodynamic data.
Myocyte Isolation and Culture. Sham-operated and paced
rabbits were anesthetized, treated with heparin, and then
intubated as above. Hearts were excised and perfused by the
Langendorff technique as described (11) with Joklik’s modi-
fied minimum medium containing hyaluronidase, collagenase,
bacterial protease, and 12.5 mM CaCl2. When the heart turned
soft, the ventricles were dissected free and cells were isolated
as described (11). This procedure typically yielded 1–2 3 107
myocytes per rabbit heart with 50–80% in rod-shaped mor-
phology. Myocytes were plated at a density of 1 3 105y35-mm
well or 1 3 106y100 mm on tissue culture plates that were
precoated with 20 mgyml of mouse laminin for 1 hr. The
myocytes were calcium-tolerant as evidenced by their quies-
cent state throughout the experiments.
Adenoviral Infection. After 5 hr the myocytes adhered to the
tissue culture plates and cells were infected with the appro-
priate titer of adenovirus in 1-ml culture medium for 100 mm
plates and 0.5 ml for 6-well dishes. The cells were incubated
with the virus for 15 min, after which culture medium was
added back to the plates. The adenoviral vector (type 5)
utilized has been described (11). Myocytes were either infected
with an empty adenoviral vector (empty Ad5) or adenoviruses
containing the transgenes for the human b2-AR (Adeno-
b2AR) or the bARKct (Adeno-bARKct).
Membrane and Cytosolic Preparation. Thirty-six hr after
adenoviral infection, cells were harvested in lysis buffer (5 mM
TriszHCl, pH 7.4y5 mM EDTA) and dounce homogenized
with 15 strokes on ice. Samples were centrifuged at 40,000 3
g for 15 min to pellet membranes and the supernatants were
concentrated in a Centricon-10 filter apparatus (Amicon).
Concentrated supernatants were kept at 0°C. Membranes were
resuspended in lysis buffer and stored in aliquots at 280°C.
Intracellular cAMP Assay. Cells were labeled overnight in
3.0 mCiyml (1 Ci 5 37 GBq) [3H]adenine (DuPontyNEN) in
medium 199 and then preincubated in minimal essential
medium with 10 mM Hepes and 1 mM 3-isobutyl-1- methyl-
xanthine (IBMX) for 30 min as described (11). For time course
experiments, the cells were subsequently stimulated with 10
mM (2)-isoproterenol (ISO) in medium containing 100 mM
ascorbic acid. For dose-response studies the ISO concentration
is explicitly stated and the cells were incubated for 15 min.
Following incubation, the medium was aspirated and 1 ml of
ice-cold stop solution (2.5% perchloric acidy100 mM cAMPy
10,000 cpm 14C) was added to each well. cAMP was deter-
mined by anion exchange chromatography, and a percent
incorporation of the total 3H uptake was calculated (11).
Radioligand Binding Assays. Binding assays were per-
formed on 25 mg of membrane protein using saturating
amounts of the b-AR-specific ligand [125I]cyanopindolol (300
pM). Nonspecific binding was determined in the presence of 20
mM alprenolol. Reactions were conducted in 500 ml of binding
buffer (75 mM TriszHCl, pH 7.4y12.5 mM MgCl2y2 mM
EDTA) at 37°C for 1 hr and terminated by vacuum-filtration
through glass-fiber filters. All assays were performed in trip-
licate, and receptor density was normalized to mg of mem-
brane protein (11).
GRK Activity Assays. Membrane extracts were prepared as
described (9, 12). Concentrated membrane extracts (100 mg of
protein) were incubated with rhodopsin-enriched rod outer
segment membranes in 75 ml of GRK lysis buffer (25 mM
TriszHCl, pH 7.4y5 mM EDTAy5 mM EGTAy10 mg of
leupeptin/mly20 mg of aprotinin/mly1 mM phenyl-methylsul-
fonyl f luoride) with 10 mM MgCl2 and 0.1 mM ATP contain-
ing [g-32P]ATP. The reactions were incubated in white light for
15 min at room temperature and quenched with 300 ml of
ice-cold lysis buffer and then centrifuged for 15 min at
13,000 3 g. Sedimented proteins were resuspended in 25 ml of
protein–gel loading dye and electrophoresed through SDSy
12% polyacrylamide gels. Phosphorylated rhodopsin was vi-
sualized by autoradiography of dried gels and GRK-mediated
phosphate incorporation was quantified using a Phosphor-
Imager (Molecular Dynamics).
Sarcolemmal Membrane Adenylyl Cyclase Activity. Crude
myocardial membranes were prepared as described above
from both control and failing hearts. Membranes (20–30 mg of
protein) were incubated for 15 min at 37°C with [a-32P]ATP
under basal conditions or in the presence of either progressive
doses of ISO or 10 mM NaF and cAMP was quantitated by
standard methods (8).
Protein Immunoblotting. Whole-cell extracts were prepared
by dounce homogenization in 5 mM TriszHCl, pH 7.4y5 mM
EDTA. A total of 80 mg of protein for each control and CHF
ventricular myocyte extract sample was electrophoresed
through 12% Trisyglycine gels and transferred to nitrocellu-
lose. Membranes were blocked in 5% nonfat dried milk in 0.1%
Tween 20 in PBS (PBS-T) for 1 hr at room temperature. The
blots were then washed in PBS-T for 15 min and then incubated
with a monoclonal bARK antibody (13) diluted 1:10,000 in 10
ml of PBS-T for 1 hr at room temperature. bARK1 was
visualized using an anti-mouseyhorseradish peroxidase-linked
secondary antibody and ECL detection (Amersham). For
protein immunoblotting of Gas and Gai, membrane fractions
were prepared as described above, and protein immunoblots
were carried out on 20 mg of membrane protein using com-
mercially available antibodies raised against Gas or Gai1–3
(Santa Cruz Biotechnology). For immunoblotting of the
bARKct after gene transfer, cytosolic extracts were prepared
as described (11), and the 30-kDa peptide was visualized after
incubation with polyclonal bARK antiserum raised against this
peptide (9, 11).
Table 1. Hemodynamic measurements after 3 weeks of ventricular pacing
Control CHF P value
HR, bpm 187 6 3 199 6 4 0.07
LVSP, mm Hg 69 6 2 60 6 2 0.01
LVEDP, mm Hg 2.5 6 0.4 7.8 6 0.4 0.00003
LV 1 dPydtmax, mm Hgysec 1,916 6 67 1,472 6 37 0.0003
LV 2 dPydtmin, mm Hgysec 1,521 6 73 1,416 6 60 0.29
For Control (prepacing values) and CHF (postpacing values measured with pacemaker off), n 5 6. HR,
heart rate [beatsymin (bpm)]; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; LV 1
dPydtmax, maximum rate of LV pressure development; LV 2 dPydtmin, maximum rate of LV pressure
decline. P values, Student’s t test.
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Statistical Analysis. Data are expressed as mean 6 SEM.
Hemodynamic values comparing pre- and postpacing mea-
surements and signaling data from different groups of myo-
cytes were evaluated using a Student’s t test. An ANOVA with
repeated measurements plus a grouping factor was performed
on the ISO dose-response data from various myocyte groups.
For all analyses, P , 0.05 was considered significant.
RESULTS
Physiological Effects of Chronic Tachycardia. Rapid ven-
tricular pacing in rabbits has been used to successfully produce
a model of CHF (14, 15). In this study, none of the animals died
during surgical instrumentation, although there was a 10%
mortality rate over the course of the 3-week pacing period.
Twenty-one days of chronic ventricular pacing at a rate of 360
beatsymin resulted in gross clinical evidence of CHF in rabbits
including biventricular dilatation, pleural effusions, and ab-
dominal ascites. In vivo hemodynamic measurements also
demonstrated LV physiologic failure (Table 1). Heart rate and
LV pressures were recorded in each rabbit prior to surgical
implantation of the pacemaker and again after the pacing
period (with pacemaker turned off). Thus, each rabbit served
as its own control. Control sham-operated rabbits showed no
difference in hemodynamics at the end of the 3-week study
period.
b-Adrenergic Signaling Abnormalities. To assess b-AR
signaling defects in the hearts of paced rabbits, ventricular
myocytes were isolated and a series of molecular analyses were
done. b-AR density in sarcolemmal membranes was deter-
mined and as shown in Fig. 1A, total b-AR density was
significantly diminished in failing myocytes compared with
sham-operated control myocytes approaching a 50% decrease.
This is similar to the level of b-AR down-regulation seen in
chronic human CHF (2). To assess functional coupling of
myocardial b-ARs, we studied adenylyl cyclase activity in
intact ventricular myocytes by measuring intracellular cAMP
accumulation. Basal cAMP production was depressed in fail-
ing myocytes (0.23 6 0.03% conversion of [3H]adenine to
[3H]cAMP, n 5 5) compared with control (sham) myocytes
(0.60 6 0.16%, n 5 5, P , 0.05) (Fig. 1B). In addition, there
was significant attenuation of adenylyl cyclase activity in failing
myocytes in response to progressive stimulation with ISO
compared with the responses of control myocytes (Fig. 1B).
Because the cellular cAMP responses were depressed in
failing cardiomyocytes, we examined the expression of bARK1
which has been shown to be elevated in human CHF (4). To
assess the expression of bARK1, we performed protein im-
munoblotting with a bARK mAb (13, 16). In whole-cell
extracts prepared from failing and control myocytes, there was
a significant '2-fold increase in bARK1 protein levels in the
CHF cells (Fig. 1C). To further assess the significance and
functional consequences of bARK1 up-regulation, we studied
GRK activity in the membrane fraction of ventricular myo-
cytes using an in vitro rhodopsin phosphorylation assay. Al-
though bARK1 is primarily a cytosolic enzyme, it requires a
membrane translocation event before its activation. This mem-
brane-localized receptor-targeted event is mediated by specific
binding of the carboxyl terminus of bARK1 and Gbg (4, 10).
As shown in Fig. 2, membrane extracts from failing myocytes
had '3-fold higher GRK activity than extracts from control
FIG. 1. b-AR signaling defects in ventricular myocytes isolated
from chronically paced rabbit hearts. (A) b-AR density was deter-
mined from myocardial sarcolemmal membranes prepared from ven-
tricular myocytes isolated from control (sham-operated) or CHF
(paced) rabbits (n 5 5 in each group; p, P , 0.05 vs. control). (B) Basal
and ISO-stimulated intracellular adenylyl cyclase activity was deter-
mined for control (open bars) and CHF ventricular myocytes (filled
bars) (n 5 5 myocyte preparations each; p P , 0.05 vs. control). (C)
Levels of expression of bARK1 in whole-cell extracts were assessed by
protein immunoblotting. Shown is the average data for five myocyte
preparations isolated from control (sham) and CHF (paced) rabbit
hearts. bARK1 densitometry values from control immunoblots were
arbitrarily set to 1 and all values were normalized to controls. The Inset
shows a representative protein immunoblot from two control and two
CHF preparations with purified bARK1 used as a marker (p, P , 0.05
vs. control).
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myocytes. To directly determine whether this significant in-
crease in GRK activity is due to enhanced membrane bARK1
activity or another GRK such as the membrane-associated
GRK5 (12), the assay was repeated in the presence of the
bARK1 mAb. It has been shown previously that this antibody
selectively inhibits bARK1 activity and does not affect GRK5
activity (13, 16). As shown in Fig. 2, the bARK1 antibody
virtually abolished the increased GRK activity in the CHF
myocyte membrane extracts whereas control myocyte mem-
brane GRK activity was unaltered by addition of the bARK1
antibody. When an antibody specific for GRK5 was added to
the assay in addition to the bARK1 antibody, both failing and
control myocyte membrane GRK activity was abolished (data
not shown). Thus, basal GRK activity in control myocyte
membranes is primarily due to GRK5, whereas CHF results in
significant increases primarily in bARK1 expression and mem-
brane translocation. However, some increase in the membrane
GRK activity in CHF may be due to GRK5.
As a final step in our biochemical analysis of failing cardi-
omyocytes, we assessed protein levels of the a-subunits of the
G proteins Gs and Gi that regulate myocardial adenylyl cyclase
activity. In human CHF, the expression and activity of the
cyclase inhibitory Gai has been shown to be elevated (17).
Protein immunoblotting revealed that membrane extracts
from CHF myocytes had control levels of the cyclase stimu-
latory Gas, but a 2-fold increase in Gai (data not shown).
Thus, myocytes isolated from paced hearts display biochemical
alterations in the b-AR-G protein-adenylyl cyclase pathway
identical to what has been found in human CHF.
Expression of Adenoviral Transgenes. Prior to determining
the functional consequences of adenovirus infection in failing
cardiomyocytes, we examined the expression of the adenoviral
transgenes. The transgenes utilized were the human b2-AR
(Adeno-b2AR) and the bARKct (Adeno-bARKct) acting as a
bARK1 inhibitor (9, 11). Control myocytes were infected with
an empty adenoviral vector (empty Ad5). Myocytes were
infected with adenoviruses at a multiplicity of infection (moi)
of 100:1, which we have previously determined to produce
optimal transgene expression in 100% of rabbit ventricular
myocytes (11). Thirty-six hours after Adeno-bARKct infec-
tion, extracts from CHF myocytes expressed significant levels
of the '30-kDa bARK1 inhibitor peptide as determined by
protein immunoblots (Fig. 3A). b2-AR transgene expression
was assessed in membranes purified from Adeno-b2AR in-
fected CHF myocytes by radioligand binding. Failing myocytes
infected with the empty Ad5 had an average b-AR density of
48.5 6 5.3 fmolymg membrane protein, which did not differ
from uninfected failing myocytes (n 5 4 each). Following
Adeno-b2AR infection, failing myocytes had a 30-fold increase
in b-AR density (1,353.8 6 194.5 fmolymg membrane protein,
n 5 5) which is '15-fold over control values (Fig. 3B).
Functional Effects of b2-AR and bARKct Gene Transfer in
Failing Myocytes. To determine the functional effects of these
two b-adrenergic based transgenes on defective b-AR-
mediated signaling in failing cardiomyocytes, intracellular
cAMP production and accumulation was studied following
adenoviral-mediated gene transfer. As shown in Fig. 4, infec-
tion of failing myocytes with Adeno-bARKct significantly
increased basal intracellular cAMP accumulation in failing
myocytes compared with equivalent myocytes infected with
empty adenovirus (1.9 6 0.6% vs. 0.8 6 0.12%, n 5 5 in each
group, P , 0.05). This enhancement of signaling was also seen
after ISO stimulation (Fig. 4). Ventricular myocytes isolated
from paced rabbits and infected with Adeno-b2AR also had an
increase in basal and ISO-stimulated intracellular cAMP pro-
duction when compared with failing myocytes treated with the
empty adenoviral vector (Fig. 4). This is significant because we
found increased levels of Gai in the failing myocytes, demon-
strating that any effects of increased Gi are overcome by
FIG. 3. Expression of the adenoviral transgenes in failing ventric-
ular myocytes. (A) Representative Western blot displaying expression
of the bARKct peptide in only Adeno-bARKct infected myocytes. (B)
Total b-AR density determined for CHF ventricular myocyte mem-
branes infected with Empty Ad5 (n 5 4) or Adeno-b2AR (n 5 5) (p,
P , 0.005 vs. CHF 1 Ad5).
FIG. 2. Myocyte membrane GRK activity. GRK activity was
determined by an in vitro rhodopsin phosphorylation assay for control
(sham) and CHF (paced) ventricular myocyte membrane extracts in
the absence and presence of a bARK mAb (bMab) which selectively
inhibits bARK activity. Shown is the mean of five separate myocyte
preparations with the inset depicting a representative experiment done
in duplicate. Phosphorylated rhodopsin is marked by the arrow (p, P ,
0.05 vs. control; #, P , 0.05 vs. CHF).
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enhanced b-AR signaling. Interestingly, the level of basal and
agonist-stimulated b-adrenergic signaling seen in failing myo-
cytes after infection with Adeno-bARKct or Adeno-b2AR was
not only significantly elevated compared with empty Ad5-
infected CHF myocytes, but significantly increased to levels
seen in normal ventricular myocytes (Fig. 4).
To determine whether myocardial b-AR desensitization in
failing myocytes was inhibited by the expression of the
bARKct, the time course of agonist-stimulated intracellular
cAMP production was studied. This data is shown in Fig. 5.
Enhanced b-AR desensitization is apparent in CHF myocytes
as there is insignificant cAMP accumulation after 5 min
compared with control myocytes, which show linear accumu-
lation up to 10 min before there is a decline in the rate due to
desensitization mechanisms. In contrast, CHF myocytes in-
fected with the bARKct show linear cAMP accumulation well
after 10 min and have not plateaued even at 50 min after ISO
administration.
DISCUSSION
In this study, we report the novel finding that b-adrenergic
signaling defects, present in failing ventricular cardiomyocytes,
can be corrected via adenoviral-mediated gene transfer. De-
ficient b-AR signaling was reversed by either overexpression of
receptor molecules or inhibition of bARK1-mediated b-AR
desensitization using a peptide inhibitor of this GRK
(bARKct). The adenoviral-mediated overexpression of the
bARKct and significant improvement in the signaling of failing
cardiomyocytes provides strong evidence for the importance of
bARK1 in the pathogenesis of CHF and provides a novel
therapeutic target for the production of positive inotropy. Our
first goal in the present study was to characterize any b-AR
alterations present in myocytes isolated from chronically paced
rabbits which were in hemodynamic failure (Table 1). Molec-
ular analysis of the b-AR system in these myocytes indicates
that this rabbit model of CHF shares biochemical properties
seen in human CHF. We found significant down-regulation of
b-ARs and functional uncoupling of the adenylyl cyclase
response as assessed by b-AR-mediated intracellular cAMP
accumulation (Fig. 1B). We also observed that the negative
regulatory proteins bARK1 (Figs. 1C and 3) and Gai were
elevated. These molecular changes likely contribute to the
cardiac dysfunction seen in CHF, particularly the loss of b-AR
inotropic reserve. Although previous studies using this exper-
imental rabbit model of CHF demonstrated functional defi-
ciencies including those present in isolated cardiomyocytes
(14, 15), none have addressed specific molecular changes
concerning the b-AR signaling system as reported here.
The discovery that bARK1 protein expression and activity
are elevated in this model of CHF (as in human CHF) adds to
recent reports that this GRK is altered during several other
cardiovascular disorders such as myocardial ischemia in the rat
heart (18), pressure overload hypertrophy in the mouse (16),
and mild human hypertension (19). Thus, it is becoming
increasingly apparent that bARK1, and GRK activity in
general, is critically involved in the pathophysiology of CHF as
well as other cardiovascular disorders. In the present study, the
increased GRK activity was seen in membrane fractions where
GRK5 is also expressed (12), however, antibody inhibition
studies demonstrated that the enhanced GRK activity was
primarily due to bARK1 (Fig. 2).
Our laboratory has been studying the physiological conse-
quences of altering the expression of myocardial proteins
including adrenergic receptors and GRKs. This was first done
using transgenic mouse models where cardiac-specific overex-
pression of b2-ARs (8) or the bARKct (9) dramatically
increased cardiac contractility. Conversely, myocardial-
targeted overexpression in transgenic mice of bARK1 (9) or
GRK5 (12) significantly depressed cardiac function. In addi-
tion, we have also reported the effects of the b2-AR and
bARKct transgenes on the b-adrenergic signaling properties
of normal rabbit ventricular myocytes isolated in culture (11).
Adenoviral-mediated gene transfer of these two transgenes
produced effects on b-AR-mediated myocardial adenylyl cy-
clase activity which were similar to those observed in the
transgenic mice, indicating that alterations in b-AR signaling
are possible following acute gene transfer.
Taken together, these studies in transgenic mice and normal
cardiomyocytes led to our hypothesis that increasing b-AR
signaling may improve the functional performance of the
FIG. 5. Time course of cAMP production. Assessment of the effect
of Adeno-bARKct infection on b-AR desensitization via a time course
of cAMP production in response to 10 mM ISO. Myocytes were
isolated from control (sham) rabbit hearts or CHF (paced) rabbit
hearts and infected with Empty Ad5 or Adeno-bARKct (n 5 4 each)
and cAMP was measured over the course of 50 min.
FIG. 4. Intracellular cAMP production in failing ventricular myo-
cytes following adenoviral-mediated gene transfer. After 36 hr of
infection with the appropriate adenovirus, control (sham) or CHF
myocytes (n 5 4 preparations each) were stimulated with increasing
concentrations of ISO. Accumulation of cAMP was expressed as
percent incorporation of the total [3H] uptake into [3H]cAMP.
Responses for CHF cells infected with Adeno-b2AR and Adeno-
bARKct were significantly elevated compared with both CHF cells
(P , 0.005, ANOVA) and control cells (P , 0.005, ANOVA) infected
with Ad5.
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failing heart. Myocytes isolated from rabbit hearts with tachy-
cardia-induced CHF provide a powerful opportunity to test
this hypothesis. Infection of failing ventricular myocytes with
Adeno-b2AR and Adeno-bARKct leads to dramatic overex-
pression of these proteins (Fig. 3). A 30-fold overexpression of
the b2-AR led to significant increases in cAMP production
both basally and after b-agonist stimulation (Fig. 4) indicating
that these overexpressed receptors are functionally coupled.
Perhaps the most significant result from this study is the
finding that cellular inhibition of bARK1 by overexpression of
the bARKct peptide not only reverses the b-AR-mediated
signaling defects of failing cardiomyocytes but improves func-
tional coupling of endogenous b-ARs to normal levels (Fig. 4).
Desensitization was clearly attenuated by Adeno-bARKct
infection as the cellular cAMP response to ISO did not plateau
during the course of the experiment while failing myocytes
infected with an empty adenovirus did not show significant
cAMP accumulation after 5 min (Fig. 5), consistent with
cAMP responses in myocytes isolated from normal control
rabbits (11). In the case of the failing myocyte, the action of
bARKct effectively inhibits the 3-fold excess of bARK1 ac-
tivity seen in these cells. Therefore, the bARKct cannot only
inhibit the endogenous activity of bARK1 in myocytes (9, 11,
20) but also the increased activity that occurs in CHF. In
addition, we have recently demonstrated that bARKct expres-
sion in hypertrophied hearts also reverses b-AR-mediated
cardiac dysfunction due to increased bARK1 expression and
activity (16). Because it is becoming increasingly apparent that
bARK1 is involved in the pathophysiology of several cardio-
vascular disorders, inhibition of bARK1-mediated b-AR de-
sensitization may have therapeutic implications beyond the
effects seen here in failing cardiomyocytes. Further substan-
tiating the potential importance of bARK1 activity as a
therapeutic target is the finding that chronic administration of
a b-antagonist to pigs resulted in lower myocardial GRK
activity (21). Interestingly, b-antagonists have also been shown
to improve mortality in patients with chronic CHF (22).
In conclusion, this study has demonstrated that impaired
b-AR-mediated signaling in ventricular myocytes, including
enhanced Gai expression, can be rescued with adenoviral-
mediated gene transfer by either restoring b-AR density or
inhibiting bARK1 activity. Thus, this study, in the setting of
CHF, is consistent with our original findings in transgenic mice
that b2-ARs and bARK1 are critical regulators of myocardial
function and represent novel potential targets for the future
development of gene therapy strategies to enhance cardiac
performance in CHF. In the case of bARK1, pharmaceutical
inhibitors of this critical GRK could also be developed which
might have similar effects. This would eliminate the need for
gene transfer protocols which are still years away from prac-
tical applications in chronic CHF.
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